What would happen if everyone got their genome sequenced? This question is no longer the stuff of science fiction. Instead, it is a research question that Senior Genetic Counselor Carrie Blout and her colleagues at the Genomes2People initiative at Brigham and Women’s hospital are trying to answer. We discuss the medical, psychological, and economic impact … Continued
News & Media
Use our Project or Categories filter to narrow down your news search.
When a newborn’s genome is sequenced, should some results be withheld?
Nearly 90 percent of participants who carried a BRCA mutation would have been missed by 23andMe’s test, geneticists found. Dr Robert Green comments, “I think people have the right to their own genetic information, but with that right comes a responsibility. If you are going to go around the medical mainstream, read the caveats.”
Dr. Robert Green, Dr. Jason Vassy, and numerous researchers share their thoughts on the Spain-based Patia that is currently offering an assessment that includes a 16-SNP polygenic risk score.
Tala Berro, MS, LCGC writes about her experiences as a minority genetic counselor during her training and clinical rotations. Berro shares, “To my fellow genetic counselors, I propose the following version of the golden rule: treat your peers as you treat your patients”.
Pediatric oncologist Dr. Lisa Diller, the Lillian Gollay Knafel Fellow at the Radcliffe Institute for Advanced Study, is exploring genetic testing in newborns that could help them escape severe health consequences.
Spring saw accomplishments by team members through numerous projects. G2P officially kicked-off the PeopleSeq consortium in Boston this January! Our very own, Carrie Blout, MS, CGC, was one of 86 Partner’s individuals awarded the Partners In Excellence Award.
Parents and clinicians have their own ideas about newborn genome sequencing. Dr. Robert Green, principal investigator of the BabySeq Project, shares a detailed analysis of the results from the study and his thoughts on the utility of genomic sequencing for newborns in clinical care.
Highlighting the changes that are happening within direct to consumer testing, experts predict that consumer genomics will become “the new normal,” with the companies in this space and healthcare providers working together to find the best path forward.
Carrie Blout, MS, CGC, Director of Research Development and Senior genetic Counselor at Genomes2People was selected as a 2019 Individual recipient of the Partners In Excellence Awards- awarded to individuals at Partners HealthCare for going above and beyond in their work efforts.
The PeopleSeq Consortium officially kicked off their NIH- funded project in Boston, bringing together a cohort of leading academic and industry collaborators.
Researchers analyzed nearly 5,000 genes looking for the risk of diseases and found that almost 10 percent of babies tested were at risk for a condition that could be treated early.
As principal investigator on the BabySeq Project, Dr. Robert Green shares the findings from the project along with discussion on the expectations and benefits of sequencing healthy babies. Green states, “Suddenly the information available in the genome of even an apparently healthy individual is looking more robust, and the prospect of preventive genomics is looking … Continued
“The larger goal of the fund is to change the way people think about medicine,”Francesco Carrozzini, son of Franca Sozzani, states. “To make medicine more proactive and accessible. By doing so, we can help prevent millions of deaths and diseases.”
In the BabySeq Study, a total of 88% of sequenced neonates had carrier status for one or more rare genetic variants known to be associated with recessive diseases.
Getting out in front of disease is the ultimate goal of DNA screening like the BabySeq project, says Dr. Robert Green, its joint director and a Harvard Medical School professor.
A trial called BabySeq, in which researchers performed genomic sequencing on 159 newborns, identified children susceptible to diseases that regular screening doesn’t look for.
Newborn DNA testing offers several potential benefits. Mainly, it could expand the number of conditions clinicians can test for before a child starts showing symptoms, giving them and patients a head start in handling the diseases.
Scientists were stunned by the number of babies with unanticipated genetic findings that could lead to disease prevention in the future.
Press Brief: The BabySeq project reports that out of the 159 newborns that were randomized to receive genomic sequencing, 15 were found to have a genetic variant for which there was a strong evidence of increased risk of a disorder that presents or is clinically manageable during childhood.
Robert Green, MD, MPH, the projects’ principal investigator suggests “These results are unexpected and exciting, suggesting that if we examine enough well-established, disease-associated genes, we will unearth monogenic risk variants in more than 10 percent of purportedly healthy individuals.”
Harry Glorikian guest this week, Dr. Robert Green, is a professor of medicine and genetics at Harvard Medical School and director of the Genomes To People research program at Brigham & Women’s Hospital and the Broad Institute of Harvard and MIT. They dig into the individual genome, how genomic data is being used, and the impact … Continued
This Fall, G2P has had exciting updates with a new PeopleSeq grant. Our team has traveled from San Diego, Atlanta, and Fort Detrick to Basel, Zurich, and Barcelona, to several conferences, presenting new data from our translational genomics research projects.
At-home genetic testing can help you understand your biology. But before delving into your DNA, consider the caveats.
From San Diego, Atlanta and Fort Detrick to Basel, Zurich and Barcelona, our team traveled to several conferences this fall, presenting new data from our translational genomics research projects.
With genomic testing running at a low cost, why aren’t more people running toward the shelves to grab direct-to-consumer testing? Read this Wired post featuring Dr. Robert Green to learn more!
Scott D. Crawford, Shawn Fayer, and Robert C. Green directly address and highlight some of the recent FDA movement in the direct-to-consumer (DTC) genetic testing space with a five-post blog compilation.
As 2019 looms before us, it is fair to say that significant—and perhaps surprising—advances will be made in the precision medicine and omics arenas.
The Washington Post brings in genetics expert Dr. Robert Green to clarify some of the misconceptions present in results of ancestry genetic testing.
Having genetic information to determine metabolic predispositions can be a powerful tool tool for staying on a nutrition program, says Robert C. Green. “In some cases, people really are motivated by hearing about something from their own DNA. We all know we have to eat better.”
Dr. Robert Green addresses a new epigenetic test that tracks molecular aging claims to show you how to stay biologically young.
Dr. Robert Green shares a concise overview of the results regarding the MedSeq and BabySeq projects presented at the American Society of Human Genetics 2018 conference.
Dr. Robert Green explains why DNA testing kits can’t reveal anyone’s complete ancestral history.
More information on newborn and adult sequencing studies unveiled at the 2018 American Society for Human Genetics Meeting in San Diego, CA. Two projects in which healthy individuals have had their genomes sequenced have revealed that searching for unanticipated genetic results in newborns and adults can unearth far more variants associated with diseases than previously thought, … Continued
“All of the crimes that are currently unsolved, which have DNA evidence, there’s now a pathway to trying to locate these perpetrators,” says Dr. Robert Green, a medical geneticist at Brigham and Women’s Hospital and a professor at Harvard Medical School.
Dr. Robert Green points to the potential of genomics not only to reunite family members and put criminals behind bars, but also to predict and prevent heritable diseases and develop new drugs.
Mike Richman of VA Research Communications interviews Dr. Jason Vassy, a clinician and researcher at the VA Boston Healthcare System. Vassy is leading a study that is focusing on whether a test for a specific gene can help patients and doctors choose the right type and dose of statin drugs, which are often used by … Continued
“Sequencing at birth could provide a template—a book of life, if you will —to predict conditions or decide what medications to use for an entire lifetime,” says Robert Green, a medical geneticist at Brigham and Women’s and professor at Harvard Medical School who is co-leading the study.
Only about 7 percent of families approached to take part in the BabySeq Project of Brigham Women’s Hospital and Boston Children’s Hospital eventually enrolled, with many citing a lack of interest in research, study logistics, and privacy concerns as reasons for declining to participate.
Listen to WBUR’s radio segment on the BabySeq Project and one of its publications.